Vinorelbine-based chemo-radiotherapy in non-small cell lung cancer

Vieri Scotti1, Calogero Saieva2, Vanessa Di Cataldo1, Alessio Bruni3, Isacco Desideri1, Silvia Bertocci1, Icro Meattini1, Lorenzo Livi1, Gabriele Simontacchi1, Carla De Luca Cardillo1, Benedetta Bendinelli2, Paolo Bastiani4, Monica Mangoni1, Benedetta Agresti1, and Giampaolo Biti1

1Department of Radiation-Oncology, University of Florence, Florence; 2 Molecular and Nutritional Epidemiology Unit, Cancer Research and Prevention Institute, ISPO, Florence; 3Department of Radiation-Oncology, University of Modena, Modena; 4Radiotherapy Unit, Ospedale Santa Maria Annunziata, Florence, Italy

ABSTRACT

Aims and background. Concomitant radio-chemotherapy improves survival of patients with locally advanced non-small cell lung cancer, with a better local-regional control.

Methods and study design. We report our experience with vinorelbine-based chemotherapy in neoadjuvant and radical settings in 43 patients. Regimens consisted of cisplatin plus vinorelbine in 74.4% patients and carboplatin plus vinorelbine in 14.0%; 11.6% underwent mono-chemotherapy with oral vinorelbine. We estimated the crude probability of death or local recurrence by the Kaplan-Meier method. Cox regression models were used to identify the main significant predictors of death or local recurrence.

Results. A significant effect of the response to treatment was shown on both local disease free-survival \((P = 0.004)\) and overall survival \((P <0.0001)\). Patients with progressive disease after primary treatment had a significantly higher risk of further relapse at both univariate \((P = 0.046)\) and multivariate regression analysis \((P = 0.014)\) than patients with a complete response. They also showed a significantly higher risk of death at both univariate \((P = 0.0005)\) and multivariate regression analysis \((P <0.0001)\) than patients with a complete response. The most common toxicity was hematologic and gastroenteric. We recorded grade III/IV leukopenia in 11%, anemia in 6%, and esophagitis in 14% of the patients.

Conclusions. Our experience showed that vinorelbine-based chemotherapy is an effective and safe regimen, in association with a platinum compound and thoracic radiotherapy.

Key words: vinorelbine, lung cancer, non-small cell lung cancer, chemotherapy, radiotherapy.

Conflict of interest statement: None declared.

Correspondence to: Vieri Scotti, Department of Radiation-Oncology, University of Florence, Viale Morgagni 85, Florence, Italy.
Tel +39-055-7547719; fax +39-055-4379930; email v.scotti@dfc.unifi.it

Received August 29, 2011; accepted April 11, 2012.